Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Retained Earnings (2020 - 2025)

HCW Biologics (HCWB) has disclosed Retained Earnings for 6 consecutive years, with -$109.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 12.4% year-over-year to -$109.2 million, compared with a TTM value of -$109.2 million through Sep 2025, down 12.4%, and an annual FY2024 reading of -$100.6 million, down 42.57% over the prior year.
  • Retained Earnings was -$109.2 million for Q3 2025 at HCW Biologics, down from -$104.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$23.2 million in Q2 2021 and bottomed at -$109.2 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$64.3 million, with a median of -$57.4 million recorded in 2023.
  • The sharpest move saw Retained Earnings crashed 83.25% in 2021, then decreased 12.22% in 2025.
  • Year by year, Retained Earnings stood at -$30.6 million in 2021, then crashed by 48.64% to -$45.5 million in 2022, then tumbled by 54.89% to -$70.5 million in 2023, then tumbled by 42.57% to -$100.6 million in 2024, then fell by 8.63% to -$109.2 million in 2025.
  • Business Quant data shows Retained Earnings for HCWB at -$109.2 million in Q3 2025, -$104.7 million in Q2 2025, and -$102.8 million in Q1 2025.